rs2197089 — LPL LPL Regulatory Variant

LPL Regulatory Variant — Your Triglyceride Clearing Speed

Lipoprotein lipase is the traffic controller of fat in your bloodstream. Every time you eat a meal containing fat, your body packages the fat into large particles called chylomicrons¹¹ chylomicrons
Triglyceride-rich particles assembled in the intestine after fat absorption and VLDL, which are then released into circulation. LPL, anchored to the walls of capillaries in muscle and fat tissue, breaks these particles down — releasing free fatty acids for energy use or storage. Without sufficient LPL activity, triglycerides pile up in the blood. The rs2197089 variant, located 1,600 bp downstream of the LPL gene, influences how much LPL your body produces, and in turn how efficiently you clear triglycerides.

The Mechanism

rs2197089 sits in a regulatory region just downstream of the LPL transcript. The A allele is associated with higher LPL gene expression — more enzyme produced, faster triglyceride clearance, lower circulating triglycerides. The G allele is linked to lower LPL expression, reduced triglyceride hydrolysis capacity, and measurably higher plasma triglyceride levels.

This is an eQTL²² eQTL
Expression quantitative trait locus — a variant that affects how much of a gene's mRNA is produced, rather than changing the protein sequence effect: the variant doesn't alter the LPL protein structure, but it modulates how much of it gets made.

The Evidence

A large study of 9,339 Chinese Han participants³³ 9,339 Chinese Han participants
Zhang et al. Association of lipoprotein lipase polymorphism rs2197089 with serum lipid concentrations and LPL gene expression. J Hum Genet, 2013 found that rs2197089 was significantly associated with decreased triglycerides (P=0.0006), and directly demonstrated the mechanism: participants carrying at least one A allele had significantly higher LPL mRNA expression in blood cells (P=0.0243). The lipid effect was triglyceride-specific with no significant effect on HDL-C overall (P=0.088), though in smokers there was a secondary HDL-raising effect (P=0.007).

Genotype-resolved data from the NPHSII prospective study⁴⁴ NPHSII prospective study
Thompson et al. Application of statistical and functional methodologies for the investigation of genetic determinants of CHD biomarkers: LPL genotype and plasma triglycerides as an exemplar. Eur J Hum Genet, 2010 of 2,786 healthy UK men quantified the stepwise effect: mean plasma triglycerides were 1.962 mmol/L in AA homozygotes, 2.060 mmol/L in AG heterozygotes, and 2.134 mmol/L in GG homozygotes — a 9% difference between the two homozygous states (beta = 0.037, P=0.0048 on log-TG scale).

The downstream cardiovascular and metabolic consequences of raised triglycerides via LPL pathway variants are well established. Mendelian randomization⁵⁵ Mendelian randomization
A technique that uses genetic variants as instrumental variables to test causal relationships, free from confounding by lifestyle factors analysis shows that LPL pathway TG-raising variants increase acute pancreatitis risk⁶⁶ LPL pathway TG-raising variants increase acute pancreatitis risk
Gentiluomo et al. Genetic variants associated with increased plasma levels of triglycerides via LPL pathway increase acute pancreatitis risk. Gastroenterology, 2021 with odds ratios of 1.55–1.76 for the highest versus lowest genetic TG-burden groups.

Practical Actions

The G allele's effect on triglycerides is primarily mediated through LPL expression, which is influenced by dietary composition. High refined carbohydrate intake and excess caloric load suppress LPL activity and raise triglycerides further in people with already-reduced baseline expression. Omega-3 fatty acids (EPA/DHA) are the most evidence-backed dietary intervention for lowering triglycerides — they work partly by upregulating LPL expression, directly complementing the mechanism relevant here. Fibrates (fenofibrate, bezafibrate) also act through the PPAR-α pathway⁷⁷ PPAR-α pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that turns on genes for fatty acid oxidation and LPL expression to increase LPL expression and are first-line pharmacotherapy for hypertriglyceridemia.

Fasting plasma triglycerides provide a direct readout of LPL efficiency. GG homozygotes benefit from annual monitoring to catch progressive elevation before it reaches the threshold for cardiovascular risk (≥1.7 mmol/L or 150 mg/dL) or pancreatitis risk (>5.6 mmol/L or 500 mg/dL).

Interactions

The rs2197089 effect on triglycerides is additive with other LPL-region variants. rs328 (LPL S447X) is a gain-of-function coding variant that increases LPL catalytic activity; carriers of the S447X X allele have notably lower triglycerides. rs326 and rs13702 (both in the LPL 3' UTR) affect LPL mRNA stability through microRNA binding sites. The combined haplotype effect across these variants is larger than any single SNP alone.

Upstream regulators matter too: APOA5 (rs3135506 S19W) modulates LPL activation and has an independent, additive triglyceride-raising effect when combined with LPL risk alleles.